ArticleFrontiers in oncology2026

Eprenetapopt in combination with carboplatin in high-grade ovarian and triple negative breast cancer cell lines with acquired resistance to olaparib.

Begoña Pineda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.